(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) The company that markets oseltamivir (Tamiflu) in Japan has announced it will launch new studies to explore whether the antiviral drug contributes to adverse psychiatric and neurologic events in teenagers.
(CIDRAP News) A new test developed by federal experts offers preliminary detection of H5 avian influenza in human patients in about 4 hours, compared with 2 to 3 days for other methods, government officials announced today.
(CIDRAP News) A routine government safety review of the antiviral drug oseltamivir (Tamiflu) revealed 12 deaths in Japanese children who were taking it, but a US Food and Drug Administration (FDA) advisory panel concluded today that the deaths were not related to it.